October 31 2017 Issue

Show description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What's Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES: Dr. Markus serves as section editor of International Journal of Stroke; serves on the editorial board for Clinical Neurology and Neurosurgery, and BMC Medicine; serves as Associate Editor for Fronteirs in Neurology; receives publishing royalties from Stroke Medicine (OUP 2016); has consulted and led a teaching session for Astra Zeneca; and has received research support from MRC, NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Eckerle and Dr. Elliot report no disclosures.Dr. Pollack has received research support from Boehringer Ingelheim, Daiichi Sankyo, CSL Behring, Janssen Pharma, AstraZeneca, and Portola; and has served as scientific consultant for Boehringer Ingelheim, BMS/Pfizer, Janssen Pharma, AstraZeneca, and Portola.